Efficacy of Seasonal Influenza Vaccine (SIV) or Flu vaccine” in cancer patients undergoing chemotherapy.

Phase 2

• Conditions: Efficacy of flu vaccine in cancer patient undergoing chemotherapy; Cancer - Any cancer

• Registration Number: ACTRN12611000306910
• Lead Sponsor: Flinders Medical centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Subjects > 18yrs with histologically/cytologically confirmed neoplasm starting chemotherapy or already on chemotherapy.

Exclusion Criteria

1. Prior immunization with SIV in the current season
2. Known sensitivity to Influenza vaccine, eggs,
antibiotics - neomycin or polymyxin.
3. History of Guillain-Barre Syndrome
4. Fever (greater than 38.5 degrees Celsius) at time of
administration of Fluvax

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sero conversion rates at 3-4 weeks after flu vaccination will be estimated from serum. Blood will be spun and serum analysed in batches, for influenza antibody levels by quantitative Haemagglutination Inhibition technique.[3-4 weeks]

Secondary Outcome Measures

Name	Time	Method
ate seroconversion at 6-7 weeks<br>Blood will be spun and serum analysed in batches, for influenza antibody levels by quantitative Haemagglutination Inhibition technique.[6-7 weeks];Sustained sero protection at 6 months<br>Blood will be spun and serum analysed in batches, for influenza antibody levels by quantitative Haemagglutination Inhibition technique.[6 months]